This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Zanett, Novell: Early Volume Plays

NEW YORK ( TheStreet) -- Several stocks trading near $5 were poised to move on above-average volume during Monday's session.

Zanett (ZANE) slipped 5 cents, or 2%, to $2.53 in early trading after the company said it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq. This comes after the stock finished at or above $1 for 10 consecutive business days from March 4 to March 17. The 50-day average daily volume for Zanett is 1.07 million.

Novell (NOVL) jumped by 29 cents, or 5.1%, to $5.93 shortly after the opening bell Monday after the software company rejected an unsolicited bid from Elliott Associates as "inadequate." Elliott had offered the conditional proposal to acquire Novell for $5.75 per share. Novell added that it believes that an exploration of alternatives is in the best interests of the company and its stockholders. The 50-day average daily volume for Novell is 9.5 million.

BioDelivery Sciences International (BDSI - Get Report) rose by 18 cents, or 4.4%, to $4.18 at the start of trading after the company announced the positive outcome of a meeting with the Food and Drug Administration on the development program for BEMA Granisetron, the company's potential treatment for the prevention of nausea and vomiting associated with cancer therapy. The FDA concurred with BioDelivery's plans to pursue a development program based on clinical pharmacokinetic data for a New Drug Application (NDA). The 50-day average daily volume for BioDelivery is 90,000.

PharmAthene (PIP - Get Report) dropped by 21 cents, or 13.3%, to $$1.50 after the biodefense company said it is pursuing various options to move forward under a contract modification announced on Feb. 23 to its existing contract with the Biomedical Advanced Research and Development Authority for the research and development of SparVax pending a final ruling under the protest. The company said it is confident that the protest is without merit and that the contract modification will be upheld. The three-month average daily volume for PharmAthene is 719,000, according to Yahoo! Finance.

-- Written by Robert Holmes in Boston.

Check out all of Monday's high-volume, under-$5 stocks at the Dollar Store

Follow Robert Holmes on Twitter and become a fan of on Facebook.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ZANE $0.07 0.00%
BDSI $13.89 0.00%
PIP $1.64 0.00%
AAPL $123.25 0.00%
FB $83.30 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs